BriaCell Therapeutics Corp. announced the imminent clinical use of a new novel, frozen formulation for its lead product candidate, Bria-IMTTM, which is currently being tested in a Phase I/IIa clinical trial with pembrolizumab listed in ClinicalTrials.gov as NCT03328026. Additionally, BriaCell will present a poster at a 2019 Keystone Symposia scientific conference, which is being held Jan. 20-24, 2019, at Fairmont Hotel Vancouver in Vancouver, British Columbia. The poster will highlight BriaCell's recent clinical and research-focused development of Bria-IMTTM and BriaDXTM, the corresponding companion diagnostic which helps identify those patients most likely to benefit from Bria-IMTTM and Bria-OTSTM. The Company further announces that BriaCell management will attend Biotech ShowcaseTM 2019, an important investor conference taking place Jan. 7-9, 2019, at Hilton San Francisco Union Square in San Francisco, California. The Company's novel, frozen formulation permits storage of cryopreserved, ready-to-inject Bria-IMTTM and cold-chain overnight transport to the clinical sites where it will be thawed prior to injection in patients with advanced breast cancer. The novel, frozen formulation of Bria-IMTTM has shown improved potency compared to the old formulation in vitro. Long term, the novel, frozen formulation is expected carry reduced per-dose costs compared to the old formulation.